Tardive dyskinesia and essential fatty acids

References

• Abilio VC, Araujo CC, Bergamo M, Calvente PR, D’Almeida V, Ribeiro Rdem A, et al. Vitamin E attenuates reserpine-induced oral dyskinesia and striatal oxidized glutathione/reduced glutathione ratio (GSSG/GSH) enhancement in rats. Progress in Neuropsychopharmacology & Biological Psychiatry 2003; 27(1)109–114
   PubMedGoogle Scholar
• Abilio VC, Silva RH, Carvalho RC, Grassl C, Calzavara MB, Registro S, et al. Important role of striatal catalase in aging- and reserpine-induced oral dyskinesia. Neuropharmacology 2004; 47(2)263–272
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic & Statistical Manual of Mental Disorders-IV- TR4th. American Psychiatric Association, Washington DC 2000
   Google Scholar
• Anderson JJ, Kask AM, Chase TN. Effects of cannabinoid receptor stimulation and blockade on catalepsy produced by dopamine receptor antagonists. European Journal of Pharmacology 1996; 295(2–3)163–168
   PubMedGoogle Scholar
• Andreassen OA, Jorgensen HA. Neurotoxicity associated with neuroleptic-induced oral dyskinesia in rats; implications for tardive dyskinesia. Progress in Neurobiology 2000; 61: 525–541
   PubMed Web of Science ®Google Scholar
• Arvindakshan M, Ghate M, Ranjekar PK, Evans DR, Mahadik SP. Supplementation with a combination of omega-3 fatty acids and antioxidants (vitamins E and C) improves the outcome of schizophrenia. Schizophrenia Research 2003; 62: 195–204
   PubMed Web of Science ®Google Scholar
• Assies J, Lieverse R, Vreken P, Wanders RJ, Dingemans PM, Linszen DH. Significantly reduced docosahexaenoic and docosapentaenoic acid concentrations in erythrocyte membranes from schizophrenic patients compared with a carefully matched control group. Biological Psychiatry 2001; 49(6)510–522
   PubMedGoogle Scholar
• Barnes TR, Liddle PF, Curson DA, Patel M. Negative symptoms, tardive dyskinesia and depression in chronic schizophrenia. British Journal of Psychiatry 1989; 7: 99–103
   Google Scholar
• Basavarajappa BS, Hungund BL. Neuromodulatory role of the endocannabinoid signaling system in alcoholism: An overview. Prostaglandins Leukotrienes Essential Fatty Acids 2002; 66: 287–299
   PubMed Web of Science ®Google Scholar
• Berger A, Crozier G, Bisogno T, Cavaliere P, Innis S, Di Marzo V. Anandamide and diet: Inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets. Proceedings of the National Academy of Science of the USA 2001; 98(11)6402–6406
   PubMedGoogle Scholar
• Brenner RR. The desaturation step in the animal biosynthesis of polyunsaturated fatty acids. Lipids 1971; 6(8)567–575
   PubMedGoogle Scholar
• Burger M, Fachinetto R, Calegari L, Paixao MW, Braga AL, Rocha JB. Effects of age on reserpine-induced orofacial dyskinesia and possible protection of diphenyl diselenide. Brain Research Bulletin 2004; 64(4)339–345
   PubMedGoogle Scholar
• Burger ME, Alves A, Callegari L, Athayde FR, Nogueira CW, Zeni G, et al. Ebselen attenuates reserpine-induced orofacial dyskinesia and oxidative stress in rat striatum. Progress in Neuropsychopharmacology & Biological Psychiatry 2003; 27(1)135–140
   PubMedGoogle Scholar
• Burger ME, Fachineto R, Alves A, Callegri L, Rocha JB. Acute reserpine and subchronic haloperidol treatment change synaptosomal brain glutamate uptake and elicit oroacial dyskinesia in rats. Brain Research 2005; 1031(2)202–210
   PubMedGoogle Scholar
• Cadet JL, Lohr JB. Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Annals of the New York Acadademy of Sciences 1989; 570: 176–185
   PubMed Web of Science ®Google Scholar
• Caligiuri MP, Jeste DV. Association of diabetes with dyskinesia in older psychosis patients. Psychopharmacology (Berlin) 2004; 176: 281–286
   PubMed Web of Science ®Google Scholar
• Carlson SE, Carver JD, House SG. High fat diets varying in ratios of polyunsaturated to saturated fatty acid and linoleic to linolenic acid: A comparison of rat neural and red cell membrane phospholipids. The Journal of Nutrition 1986; 116(5)718–725
   PubMedGoogle Scholar
• Casey DE. Tardive dyskinesia: Non-dopaminergic treatment approaches. Psychopharmacology 1985; 2: 137–144
   Google Scholar
• Casey DE. Pathophysiology of antipsychotic drug-induved movement disorders. Journal of Clinical Psychology 2004; 65(9)25–28
   Google Scholar
• Castilho RF, Hansson O, Brundin P. Improving the survival of grafted embryonic dopamine neurons in rodent models of Parkinson's disease. Progress in Brain Research 2000; 127: 203–231
   PubMedGoogle Scholar
• Chong SA, Tan EC, Tan CH, Mythily S, Chan YH. Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics 2003; 116(1)51–54
   Google Scholar
• Chouinard G, Annable L, Ross-Chouinard A, Mercier P. A 5-year prospective longitudinal study of tardive dyskinesia: Factors predicting appearance of new cases. Journal of Clinical Psychopharmacology 1988; 8(4)21S–26S
   Google Scholar
• Clifford JJ, Drago J, Natoli AL, Wong JY, Kinsella A, Waddington JL, et al. Essential fatty acids given from conception prevent topographies of motor deficit in a transgenic model of Huntington's disease. Neuroscience 2002; 109(1)81–88
   PubMedGoogle Scholar
• Connor WE, DeFrancesco CA, Connor SL. N-3 fatty acids from fish oil. Effects on plasma lipoproteins and hypertriglyceridemic patients. Annals of the New York Academy of Sciences 1993; 683: 16–34
   PubMed Web of Science ®Google Scholar
• Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: A systematic review of 1-year studies. American Journal of Psychiatry 2004; 161(3)414–425
   PubMed Web of Science ®Google Scholar
• Costall B, Kelly ME, Naylor RJ. The antidyskinetic action of dihomo-gamma-linolenic acid in the rodent. British Journal of Pharmacology 1984; 83(3)733–740
   PubMedGoogle Scholar
• Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science 1993; 262(5134)689–695
   PubMed Web of Science ®Google Scholar
• Csernansky JG, Kaplan J, Holman CA, Hollister LE. Serum neuroleptic activity, prolactin, and tardive dyskinesia in schizophrenic outpatients. Psychopharmacology (Berl) 1983; 81(2)115–118
   PubMedGoogle Scholar
• Cunningham Owens DG. Tardive dyskinesia. A Guide to the Extrapyramidal Side-Effects of Antipsychotic drugs, DG Cunningham Owens. University Press, Cambridge 1999; 166–226
   Google Scholar
• de Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ. Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. Journal of Clinical Psychopharmacology 2005; 25: 448–456
   PubMed Web of Science ®Google Scholar
• D'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH. The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: Implications for psychosis. Neuropsychopharmacology 2004; 29: 1558–1572
   PubMed Web of Science ®Google Scholar
• Das UN, Vaddadi KS. Essential fatty acids in Huntington disease. Nutrition 2004; 20(10)942–947
   PubMedGoogle Scholar
• Delfs JM, Ciaramitaro VM, Soghomonian JJ, Chesselet MF. Unilateral nigrostriatal lesions induce a bilateral increase in glutamate decarbocylase messenger RNA in the reticular thalamic nucleus. Neuroscience 1996; 71(2)383–395
   PubMedGoogle Scholar
• Deshpande SN, Varma PG, Semwal P, Rao AR, Bhhatia T, Nimgaonkar VL, et al. Serotonin receptor gene polymorphism and their association with tardive dyskinesia among schizophrenia patients from North India. Psychiatric Genetics 2005; 15(3)157–158
   PubMedGoogle Scholar
• Dixon L, Weiden PJ, Haas G, Sweeney J, Frances AJ. Increased tardive dyskinesia in alcohol-abusing schizophrenic patients. Comprehensive Psychiatry 1992; 33(2)121–122
   PubMedGoogle Scholar
• Ellingrod VL, Schultz SK, Arndt S. Abnormal movements and tardive dyskinesia in smokers and non-smokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy 2002; 22(11)1416–1419
   PubMedGoogle Scholar
• Evans DR, Parikh VV, Khan MM, Coussons C, Buckley PF, Mahadik SP. Red blood cell membrane essential fatty acid metabolism in early psychotic patients following antipsychotic drug treatment. Prostaglandins, Leukotrienes and Essential Fatty Acids 2003; 69(6)393–399
   PubMed Web of Science ®Google Scholar
• Fenton WS, Hibbeln J, Knable M. Essential fatty acids, lipid membrane abnormalities, and the diagnosis and treatment of schizophrenia. Biological Psychiatry 2000; 47(1)8–21
   PubMedGoogle Scholar
• Gattaz WF, Emrich A, Behrens S. Vitamin E attenuates the development of haloperidol-induced dopaminergic hypersensitivity in rats: Possible implications for tardive dyskinesia. Journal of Neural Transmission. General Section 1993; 92(2–3)197–201
   PubMedGoogle Scholar
• Gattaz WF, Hubner CV, Nevalainen TJ, Thuren T, Kinnunen PK. Increased serum phospholipase A2 activity in schizophrenia: A replication study. Biological Psychiatry 1990; 28(6)495–501
   PubMed Web of Science ®Google Scholar
• Gattaz WF, Kollisch M, Thuren T, Virtanen JA, Kinnunen PK. Increased plasma phospholipase-A2 activity in schizophrenic patients: Reduction after neuroleptic therapy. Biological Psychiatry 1987; 22(4)421–426
   PubMed Web of Science ®Google Scholar
• Glass M, Draunow M, Faull RL. The pattern of neurodegeneration in Huntington's disease: A comparative study of cannabinoid, dopamine, adenosine and GABA(A) receptor alterations in the human basal ganglia in Huntington's disease. Neuroscience 2000; 97(3)505–519
   PubMed Web of Science ®Google Scholar
• Glass M, Faull RL, Dragunow M. Loss of cannabinoid receptors in the substantia nigra in Huntinton's disease. Neuroscience 1993; 56(3)523–527
   PubMedGoogle Scholar
• Glazer WM, Moore DC. Psychiatric treatment programs: the continuous service model. Employment Benefits Journal 1993; 18(2)30–36
   PubMedGoogle Scholar
• Glazer WM, Moore DC, Schooler NR, Brenner LM, Morgenstern H. Tardive dyskinesia. A discontinuation study. Archives of General Psychiatry 1984; 41(6)623–627
   PubMedGoogle Scholar
• Glen AI, Glen EM, Horrobin DF, Vaddadi KS, Spellman M, Morse-Fisher N, et al. A red cell membrane abnormality in a subgroup of schizophrenic patients: Evidence for two diseases. Schizophrenia Research 1994; 12(1)53–61
   PubMedGoogle Scholar
• Gorriti MA, Rodriguez de Fonseca F, Navarro M, Palomo T. Chronic (-)-delta9-tetrahydrocannabinol treatment induces sensitization to the psychomotor effects of amphetamine in rats. European Journal of Pharmacology 1999; 365(2–3)133–142
   PubMed Web of Science ®Google Scholar
• Grimm JW, Chapman MA, Zahm DS, See RE. Decreased choline acetyltransferase immunoreactivity in discrete striatal subregions following chronic haloperidol in rats. Synapse 2001; 39(1)51–57
   PubMedGoogle Scholar
• Guy W, Ban TA, Wilson WH. The prevalence of abnormal involuntary movements among chronic schizophrenics. International Clinical Psychopharmacology 1986; 1(2)134–144
   PubMedGoogle Scholar
• Halliwell B, Gutteridge JM. The importance of free radicals and catalytic meta ions in human diseases. Molecular Aspects of Medicine 1985; 8(2)89–193
   PubMed Web of Science ®Google Scholar
• Hensley R, Floyd RA. Reactive oxygen species and protein oxidation in aging: A look back, a look ahead. Archives of Biochemistry and Biophysics 2002; 397(2)377–383
   PubMed Web of Science ®Google Scholar
• Henzl MR. Perspectives and clinical significance of eicosanoids in immunology, endocrinology and metabolic regulation. The Eicosanoids, P Curtis-Prior. Wiley & Sons, UK 2004; 227–236
   Google Scholar
• Herkenham M, Lynn AB, de Costa BR, Richfield EK. Neuronal localization of cannabinoid receptors in the basal ganglia of the rat. Brain Research 1991; 547: 267–274
   PubMed Web of Science ®Google Scholar
• Hibblen J. Long-chain polyunsaturated fatty acids in depression and related conditions. Phospholipid Spectrum Disorder in Psychiatry, M Peet, I Glen, DF Horrobin. Marius Press, Carnforth 1999; 195–210
   Google Scholar
• Hibbeln JR, Makino KK, Martin CE, Dickerson F, Boronow J, Fenton WS. Smoking, gender, and dietary influences on erythrocyte essential fatty acid composition among patients with schizophrenia or schizoaffective disorder. Biological Psychiatry 2003; 53: 431–441
   PubMedGoogle Scholar
• Holt DJ, Herman MM, Hyde TM, Kleinman JE, Sinton CM, German DC, et al. Evidence for a deficit in cholinergic interneurons in the striatum in schizophrenia. Neuroscience 1999; 94(1)21–31
   PubMedGoogle Scholar
• Hori H, Ohmori O, Shinkai T, Kojima H, Okano C, Suzuki T, et al. Manganese superoxide dismutase gene polymorphism and schizophrenia: Relation to tardive dyskinesia. Neuropsychopharmacology 2000; 23(2)170–177
   PubMed Web of Science ®Google Scholar
• Horrobin DF. Fatty acid levels in the brains of schizophrenics and normal controls. Biological Psychiatry 1991; 30(8)795–805
   PubMedGoogle Scholar
• Horrobin DF. The membrane phospholipid hypothesis as a biochemical basis for the neurodevelopmental concept of schizophrenia. Schizophrenia Research 1998; 30(3)193–208
   PubMed Web of Science ®Google Scholar
• Horrobin DF. The effects of antipsychotic drugs on membrane phospholipids: A possible novel mechanism of action of clozapine. Phospholipid Spectrum Disorder in Psychiatry, IGaDFH Malcolm Peet. Marius Press, LancashireUK 1999a; 113–117
   Google Scholar
• Horrobin DF. The phospholipid concept of psychiatric disorders and its relationship to the neurodevelopment concept of schizophrenia. Phospholipid Spectrum Disorder in Psychiatry, IGaDFH Malcolm Peet. Marius Press, LancashireUK 1999b; 3–20
   Google Scholar
• Horrobin DF. Omega-3 fatty acid for schizophrenia. American Journal of Psychiatry 2003; 160(1)188–189
   PubMed Web of Science ®Google Scholar
• Horrobin DF, Glen AI, Vaddadi KS. The membrane hypothesis of schizophrenia. Schizophrenia Research 1994; 13(3)195–207
   PubMed Web of Science ®Google Scholar
• Inada T, Senoo H, Iijima Y, Yamauchi T, Yagi G. Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatric Genetics 2003; 13(3)163–168
   PubMed Web of Science ®Google Scholar
• Jeding I, Evans PJ, Akanmu D, Dexter D, Spencer JD, Aruoma OI, Jenner P, Halliwell B. Characterization of the potential antioxidant and pro-oxidant actions of some neuroleptic drugs. Biochemical Pharmacology 1995; 49: 359–365
   PubMed Web of Science ®Google Scholar
• Jenkins AP, Thompson RP. Does the fatty acid profile of dietary fat influence its trophic effect on the small intestinal mucosa. Gut 1993; 34(3)358–264
   PubMedGoogle Scholar
• Jeste DV, Caligiuri MP, Paulsen JS, Heaton RK, Lacro JP, Harris MJ, et al. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients. Archives of General Psychiatry 1995; 52(9)756–765
   PubMedGoogle Scholar
• Jeste DV, Karson CN, Iager AC, Bigelow LB, Wyatt RJ. Association of abnormal involuntary movements and negative symptoms. Psychopharmacology Bulletin 1984; 20(3)380–381
   PubMedGoogle Scholar
• Jeste DV, Lohr JB, Manley M. Study of neuropathologic changes in the striatum following 4, 8 and 12 months of treatment with flupheazine in rats. Psychopharmacology (Berl) 1992; 106(2)154–160
   PubMed Web of Science ®Google Scholar
• Jeste DV, Lohr JB, Clark K, Wyatt RJ. Pharmacological treatments of tardive dyskinesia in the 1980s. Journal of Clinical Psychopharmacology 1988; 8(4)38–48
   PubMedGoogle Scholar
• Kaiya H. Prostaglandin E1 treatment of schizophrenia. Biological Psychiatry 1984; 19: 457–462
   PubMed Web of Science ®Google Scholar
• Kane JM, Woerner M, Lieberman J. Tardive dyskinesia: Prevalence, incidence and risk factors. Journal of Clinical Psychopharmacology 1988; 39(4)473–481
   Google Scholar
• Kapur S, Seeman P. Does fast association from the dopamine D2 receptor explain the action of atypical antipsychotcs? A new hypothesis. American Journal of Psychiatry 2001; 158(3)360–369
   PubMed Web of Science ®Google Scholar
• Kassis V, Sondergaard J. Prostaglandin E1 in normal human skin: Mthodological evaluation, topographical distribution and data related to sex and age. Archives for Dermatological Research 1983; 275(1)9–13
   PubMedGoogle Scholar
• Katayama K, Ueda N, Kurahashi Y, Suzuki H, Yamamoto S, Kato I. Distribution of anandamide amidohydrolase in rat tissues with special reference to small intestine. Biochimica et Biophysica Acta 1997; 1347(2–3)212–218
   PubMedGoogle Scholar
• Khan MM, Parikh VV, Mahadik SP. Antipsychotic drugs differentially modulate apolipoprotein D in rat brain. Journal of Neurochemistry 2003; 86(5)1089–1100
   PubMedGoogle Scholar
• Klawans HL, Jr., Rubovits R. An experimental model of tardive dyskinesia. Journal of Neural Transmmission 1972; 33(3)235–246
   PubMed Web of Science ®Google Scholar
• Kropp S, Kern V, Lange K, Degner D, Hajak G, Kornhuber J, et al. Oxidative stress during treatment with first- and second-generation antipsychotics. The Journal of Neuropsychiatry and Clinical Neurosciences 2005; 17(2)227–231
   PubMed Web of Science ®Google Scholar
• Lai IC, Wang YC, Lin CC, Bai YM, Liao DL, Yu SC, et al. Negative association between Catechol-O-methyltransferase (COMT) gene Val158Met polymorphism and persistent tardive dyskinesia in schizophrenia. Journal of Neural Transmission 2005; 112(8)1107–1113
   PubMedGoogle Scholar
• Lastres-Becker I, Hansen HH, Berrendero F, De Miguel R, Perez-Rosado A, Manzanares J, et al. Alleviation of motor hyperactivity and neurochemical deficits by endocannabinoid uptake inhibition in a rat model of Huntington's disease. Synapse 2002; 44(1)23–35
   PubMed Web of Science ®Google Scholar
• Lees AJ. Parkinson's disease and dementia. Lancet 1985; 1(8419)43–44
   PubMedGoogle Scholar
• Lieberman JA, Saltz BL, Johns CA, Pollack S, Borenstein M, Kane J. The effects of clozapine on tardive dyskinesia. British Journal of Psychiatry 1991; 158: 503–510
   PubMed Web of Science ®Google Scholar
• Lindenmayer JP, Kay SR, Opler L. Positive and negative subtypes in acute schizophrenia. Comprehensive Psychiatry 1984; 25(4)455–464
   PubMedGoogle Scholar
• Liou YJ, Wang YC, Bai YM, Lin CC, Yu SC, Liao DL, et al. Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology 2004; 49(4)167–173
   PubMed Web of Science ®Google Scholar
• Lohr JB, Cadet JL, Lohr MA, Larson L, Wasli E, Wade L, Hylton R, Vidoni C, Jeste DV, Wyatt RJ. Vitamin E in the treatment of tardive dyskinesia: The possible involvement of free radical mechanisms. Schizophrenia Bulletin 1988; 14: 291–296
   PubMed Web of Science ®Google Scholar
• Lohr JB. Oxygen radicals and neuropsychiatric illness. Some speculations. Archives of General Psychiatry 1991; 48(12)1097–1106
   PubMed Web of Science ®Google Scholar
• Lohr JB, Browning JA. Free radical involvement in neuropsychiatric illnesses. Psychopharmacology Bulletin 1995; 31(1)159–165
   PubMedGoogle Scholar
• Lohr JB, Kuczenski R, Niculescu AB. Oxidative mechanisms and tardive dyskinesia. CNS Drugs 2003; 17(1)47–62
   PubMed Web of Science ®Google Scholar
• Lucey JV, Dinan TG. Oroacial dyskinesia and the alcohol dependence syndrome. Psychological Medicine 1992; 22(1)79–83
   PubMedGoogle Scholar
• Mahadik SP, Evans DR. Is schizophrenia a metabolic brain disorder? Membrane phospholipid dysregulation and its therapeutic implications. The Psychiatric Clinics of North America 2003; 26(1)85–102
   PubMed Web of Science ®Google Scholar
• Mahadik SP, Scheffer RE. Oxidative injury and potential use of antioxidants in schizophrenia. Prostaglandins, Leukotrines and Essential Fatty Acids 1996; 55(1–2)45–54
   PubMed Web of Science ®Google Scholar
• Mahadik SP, Laev H, Korenovsky A, Karpiak SE. Haloperidol alters rat cholinergic system: Enzymatic and morphological analyses. Biological Psychiatry 1988; 24(2)199–217
   PubMedGoogle Scholar
• Mahadik SP, Mukherjee S, Correnti EE, Kelkar HS, Wakade CG, Costa RM, et al. Plasma membrane phospholipid and cholesterol distribution of skin fibroblasts from drug-naive patients at the onset of psychosis. Schizophrenia Research 1994; 13(3)239–247
   PubMedGoogle Scholar
• Mailleux P, Vanderhaeghen JJ. Distribution of neuronal cannabinoid receptor in the adult rat brain: A comparative receptor binding radio-autography and in situ hybridization histochemistry. Neuroscience 1992a; 48(3)655–668
   PubMed Web of Science ®Google Scholar
• Mailleux P, Vanderhaeghen JJ. Age-related loss of cannabinoid receptor binding sites and mRNA in the rat striatum. Neuroscience Letter 1992b; 147(2)179–181
   PubMed Web of Science ®Google Scholar
• Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R. Tardive dyskinesia in the era of typical and atypical antipsychotics, Part 1: Pathophysiology and mechanism of induction. Canadian Journal of Psychiatry 2005a; 50(9)541–547
   PubMedGoogle Scholar
• Margolese HC, Chouinard G, Kolivakis TT, Beauclair L, Miller R, Annable L. Tardive dyskinesia in the era of typical and atypical antipsychotics, Part 2: Incidence and management strategies in patients with schizophrenia. Canadian Journal of Psychiatry 2005b; 50(11)703–714
   PubMed Web of Science ®Google Scholar
• Matsumoto C, Shinkai T, Hori H, Ohmori O, Nakamura J. Polymorphisms of dopamine degradation enzyme (COMT and MAO) genes and tardive dyskinesia in patients with schizophrenia. Psychiatry and Research 2004; 127(1–2)1–7
   PubMedGoogle Scholar
• McGrath JJ, Soares KV. Benzodiazepines for neuroleptic-induced tardive dyskinesia. The Cochrane Database of Systematic Reviews. 2000a, (2), Art. No: CD000205
   Google Scholar
• McGrath JJ, Soares KV. Cholinergic medication for neuroleptic-induced tardive dyskinesia. The Cochrane Database of Systematic Reviews. 2000b, (2), Art. No: CD000207
   Google Scholar
• McGrath JJ, Soares KV. Miscellaneuous treatments for neuroleptic-induced tardive dyskinesia. The Cochrane Database of Systematic Reviews. 2000c, (2), Art. No: CD000208
   Google Scholar
• McGrath JJ, Soares KV. Neuroleptic reduction and/or cessation and neuroleptics as specific treatments for tardive dyskinesia. The Cochrane Database of Systematic Reviews. 2000d, (2), Art. No: CD000459
   Google Scholar
• Mellor JE, Laugharne JD, Peet M. Schizophrenic symptoms and dietary intake of n-3 fatty acids. Schizophrenia Research 1995; 18(1)85–86
   PubMedGoogle Scholar
• Miller DD. Clinical correlates of tardive dyskinesia in schizophrenia: Baseline data from the CATIE schizophrenia trial. Schizophrenia. Research 2005; 80(1)33–43
   PubMed Web of Science ®Google Scholar
• Miller R, Chouinard G. Loss of striatal cholinergic neurons as a basis for tardive dyskinesia and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia. Biological Psychiatry 1993; 34(10)713–738
   PubMed Web of Science ®Google Scholar
• Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Archives of General Psychiatry 1993; 50(9)723–733
   PubMed Web of Science ®Google Scholar
• Mukherjee S, Wisniewski A, Bilder R, Sackeim HA. Possible association between tardive dyskinesia and altered carbohydrate metabolism. Archive of General Psychiatry 1985; 42: 205
   PubMedGoogle Scholar
• Naidu PS, Singh A, Kulkarni SK. Reversal of haloperidol-induced orofacial dyskinesia by quercetin, a bioflavonoid. Psychopharmacology (Berl) 2003b; 167(4)418–423
   PubMedGoogle Scholar
• Naidu PS, Singh A, Kaur P, Sandhir R, Kulkarni SK. Possible mechanism of action in melatonin attenuation of haloperidol-induced orofacial dyskinesia. Pharmacology Biochemistry and Behaviour 2003a; 74(3)641–648
   PubMed Web of Science ®Google Scholar
• Newcomer JW. Metabolic risk during antipsychotic treatment. Clinical Therapeutics 2004; 26(12)1936–1946
   PubMedGoogle Scholar
• Nikoloff D, Shim JC, Fairchild M, Patten N, Fijal BA, Koch WH, et al. Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. The Pharmacogenomics Journal 2002; 2(6)400–407
   PubMedGoogle Scholar
• Nilsson A, Horrobin DF, Rosengren A, Waller L, Adlerberth A, Wilhelmsen L. Essential fatty acids and abnormal involuntary movements in the general male population: A study of men born in 1933. Prostaglandins, Leukotrienes and Essential Fatty Acids 1996; 55: 83–87
   PubMedGoogle Scholar
• Nohria V, Vaddadi KS. Tardive dyskinesia and essential fatty acids: An animal model study. Clinical uses of essential fatty acids, DF Horrobin. Eden Press, Montreal 1982; 199–204
   Google Scholar
• Olivera AA, Kiefer MW, Manley NK. Tardive dyskinesia in psychiatric patients with substance use disorders. American Journal of Drug and Alcohol Abuse 1990; 16: 57–66
   PubMed Web of Science ®Google Scholar
• Opler LA, Kay SR, Rosado V, Lindenmayer JP. Positive and negative symptoms in chronic schizophrenic patients. The Journal of Nervous and Mental Disease 1984; 172(6)317–325
   PubMedGoogle Scholar
• Pae CU, Yu HS, Kim JJ, Lee CU, Lee SJ, Jun TY, et al. Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. International Journal of Neuropsychpharmacology 2004; 7(4)495–500
   PubMedGoogle Scholar
• Patsopoulos NA, Nitzani EE, Zintzaras E, Ioannidis JP. Cyp2D6 polymorphism and the risk of tardive dyskinesia in schizophrenia: A meta-analyses. Pharmacogenetics and Genomics 2005; 15(3)151–158
   PubMedGoogle Scholar
• Paulsen JS, Caligiuri MP, Palmer B, McAdams LA, Jeste DV. Risk factors for orofacial and limbtruncal tardive dyskinesia in older patients: A prospective longitudinal study. Psychopharmacology (Berl) 1996; 123(4)307–314
   PubMedGoogle Scholar
• Peet M, Brind J, Ramchand CN, Shah S, Vankar GK. Two double-blind placebo-controlled pilot studies of eicosapentaenoic acid in the treatment of schizophrenia. Schizophrenia Research 2001; 49(3)243–251
   PubMed Web of Science ®Google Scholar
• Peet M, Laugharne JD, Mellor J, Ramchand CN. Essential fatty acid deficiency in erythrocyte membranes from chronic schizophrenic patients, and the clinical effects of dietary supplementation. Prostaglandins, Leukorienes and Essential Fatty Acids 1996; 55(1–2)71–75
   PubMedGoogle Scholar
• Peet M, Laugharne JD, Rangarajan N, Horrobin DF, Reynolds G. Depleted red cell membrane essential fatty acids in drug treated schizophrenic patients. Journal of Psychiatric Research 1995; 29: 227–232
   PubMedGoogle Scholar
• Pertwee RG. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacology & Therapeutics 1997; 74(2)129–180
   PubMed Web of Science ®Google Scholar
• Piomelli D, Guiffrida A, Calignano A, Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends in Pharmacological Sciences 2000; 21(6)218–224
   PubMed Web of Science ®Google Scholar
• Polydoro M, Schroder N, Lima MN, Caldana F, Laranja DC, Bromberg E, et al. Haloperidol- and clozapine-induced oxidative stress in rat brain. Pharmacology, Biochemistry and Behaviour 2004; 78(4)751–756
   PubMedGoogle Scholar
• Pryor GT, Larsen FF, Husain S, Braude MC. Interactions of delta9-tetrahydrocannabinol with d-amphetamine, cocaine, and nicotine in rats. Pharmacology, Biochemistry and Behaviour 1978; 8(3)295–318
   PubMedGoogle Scholar
• Puri BK, Richardson AJ. Sustained remission of positive and negative symptoms of schizophrenia following treatment with eicosapentaenoic acid. Archives of General Psychiatry 1998; 55(2)188–189
   PubMedGoogle Scholar
• Puri BK, Bydder GM, Counsell SJ, Corridan BJ, Richardson AJ, Hajnal JV, et al. MRI and neuropsychological improvement in Huntington disease following ethyl-EPA treatment. NeuroReport 2002; 13(1)123–126
   PubMedGoogle Scholar
• Puri BK, Leavitt BR, Hayden MR, Ross CA, Rosenblatt A, Greenamyre JT, et al. Ethyl-EPA in Huntington disease: A double-blind, randomized, placebo-controlled trial. Neurology 2005; 65(2)286–292
   PubMed Web of Science ®Google Scholar
• Reynolds GP, Templeman LA, Zhang ZJ. The role of 5-HT2C receptor polymorphisms in the pharmacogenetics of antipsychotic drug treatment. Progress in Neuropsychopharmacological and Biological Psychiatry 2005; 29: 1021–1028
   PubMed Web of Science ®Google Scholar
• Richardson MA, Pass R, Bregman Z, Craig TJ. Tardive dyskinesia and depressive symptoms in schizophrenics. Psychopharmacology Bulletin 1985; 21(1)130–135
   PubMedGoogle Scholar
• Richfield EK, Herkenham M. Selective vulnerability in Huntington's disease: Preferential loss of cannabinoid receptors in lateral globus pallidus. Annals of Neurology 1994; 36: 577–584
   PubMed Web of Science ®Google Scholar
• Ross DE, Thomas M, Booth M, Weinborn M. Rate of tardive dyskinesia in hospitalized patients. American Journal of Psychiatry 2005; 162: 816
   PubMedGoogle Scholar
• Sarsilmaz M, Songur A, Ozyurt H, Kus I, Ozen OA, Ozyurt B, et al. Potential role of dietary omega-3 essential fatty acids on some oxidant/antioxidant parameters in rats’ corpus striatum. Prostaglandins, Leukotrienes, and Essential Fatty Acids 2003; 69(4)253–259
   PubMedGoogle Scholar
• See RE, Lynch AM. Duration-dependent increase in striatal glutamate following prolonged fluphenazine administration in rats. European Journal of Pharmacology 1996; 308(3)279–282
   PubMedGoogle Scholar
• Segman RH, Heresco-Levy U, Yakir A, Goltser T, Strous R, Greenberg DA, et al. D3 receptor gene polymorphism on abnormal involuntary movements in chronic schizophrenia. Biological Psychiatry 2002; 51(3)261–263
   PubMedGoogle Scholar
• Shamir E, Barak Y, Shalman I, Laudon M, Zisapel N, Tarrasch R, et al. Melatonin treatment for tardive dyskinesia: A double-blind placebo controlled crossover study. Archives of General Psychiatry 2001; 58(11)1049–1052
   PubMed Web of Science ®Google Scholar
• Silvestri S, Seeman MV, Negrete JC, Houle S, Shammi CM, Remington GJ, et al. Increased dopamine D2 receptor binding after long-term treatment with antipsychotics in humans: A clinical PET study. Psychopharmacology (Berl) 2000; 152(2)174–180
   PubMed Web of Science ®Google Scholar
• Singh A, Naidu PS, Kulkarni SK. Possible antioxidant and neuroprotective mechanisms of FK506 in attenuating haloperidol-induced orofacial dyskinesia. European Journal of Pharmacology 2003; 477(2)87–94
   PubMedGoogle Scholar
• Soares KV, McGrath JJ. Vitamine E for neuroleptic-induced tardive dyskinesia. The Cochrane Database of Systematic Reviews. 2001, (Issue 4), Art. No: CD000209
   Google Scholar
• Soares KV, McGrath JJ, Deeks JJ. Gamma-aminobutyric acid agonists for neuroleptic-induced tardive dyskinesia. The Cochrane Database of Systematic Reviews. 2001, (Issue 2), Art. No: CD000203
   Google Scholar
• Tan EC, Chong SA, Mahendran R, Dong F, Tan CH. Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism in the serotonin type 2A receptor. Biological Psychiatry 2001; 50(2)144–147
   PubMedGoogle Scholar
• Tiwari AK, Deshpande SN, Rao AR, Bhatia T, Lerer B, Nimgaonkar VL, et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene. Schizophrenia Research 2005; 75(1)21–26
   PubMedGoogle Scholar
• Tsai G, Goff DC, Chang RW, Flood J, Baer L, Coyle JT. Markers of glutamatergic neurotransmission and oxidative stress associated with tardive dyskinesia. The America Journal of Psychiatry 1998; 155(9)1207–1213
   PubMedGoogle Scholar
• Tsay HJ, Wang P, Wang SL, Ku HH. Age-associated changes of superoxide dismutase and catalase activities in the rat brain. Journal of Biomedical Science 2000; 7(6)466–474
   PubMedGoogle Scholar
• Vaddadi KS. Essential fatty acids and neuroleptic drug induced tardive dyskinesia: Preliminary clinical observations. IRCS Medical Science 1984; 12: 678–679
   Google Scholar
• Vaddadi KS, Courtney P, Gilleard CJ, Manku MS, Horrobin DF. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Research 1989; 27(3)313–323
   PubMedGoogle Scholar
• Vaddadi KS, Gilleard CJ, Soosai E, Polonowita AK, Gibson RA, Burrows GD. Schizophrenia, tardive dyskinesia and essential fatty acids. Schizophrenia Research 1996; 20(3)287–294
   PubMedGoogle Scholar
• Vaddadi KS, Soosai E, Chiu E, Dindjan PA. A randomized, placebo-controlled, double-blind study of treatment of Huntington's disease with unsaturated fatty acids. NeuroReport 2002; 13: 29–33
   PubMed Web of Science ®Google Scholar
• Van Raamsdonk JM, Pearson J, Rogers DA, Lu G, Barakauskas VE, Barr AM, et al. Ethyl-EPA treatment improves motor dysfunction, but not neurodegeneration in the YAC128 mouse model of Huntington disease. Experimental Neurology 2005; 196(2)266–272
   PubMedGoogle Scholar
• Vinod KY, Hungund BL. Endocannabinoid lipids and mediated system: Implications for alcoholism and neuropsychiatric disorders. Life Sciences 2005; 77(14)1569–1583
   PubMedGoogle Scholar
• Vinod KY, Arango V, Xie S, Kassir SA, Mann JJ, Cooper TB, et al. Elevated levels of endocannabinoids and CB1 receptor-mediated G-protein signaling in the prefrontal cortex of alcoholic suicide victims. Biological Psychiatry 2005; 57(5)480–486
   PubMed Web of Science ®Google Scholar
• Waddington JL. Schizophrenia, affective psychoses, and other disorders treated with neuroleptic drugs: The enigma of tardive dyskinesia, its neurobiological determinants, and the conflict of paradigms. International Reviews in Neurobiology 1989; 31: 297–353
   PubMedGoogle Scholar
• Waddington JL. Psychopathological and cognitive correlates of tardive dyskinesia in schizophrenia and other disorders treated with neuroleptic drugs. Advances in Neurology 1995; 65: 211–229
   PubMedGoogle Scholar
• Waddington JL, Youssef HA. Late onset involuntary movements in chronic schizophrenia: Relationship of ‘tardive’ dyskinesia to intellectual impairment and negative symptoms. British Journal of Psychiatry 1986; 149: 616–620
   PubMed Web of Science ®Google Scholar
• Wang L, Liu J, Harvey-White J, Zimmer A, Kunos G. Endocannabinoid signaling via cannabinoid receptor 1 is involved in ethanol preference and its age-dependent decline in mice. Proceedings of the National Academy of Science USA 2003; 100(3)1393–1398
   PubMedGoogle Scholar
• Watanabe S, Doshi T. n-3 Polyunsaturated fatty acid (PUFA) deficiency elevates and n-3 PUFA enrichment reduces brain 2-arachidonoylglycerol level in mice. Prostaglandins, Leukotrienes and Essential Fatty Acids 2003; 69(1)51–59
   PubMedGoogle Scholar
• Wickens AP. Ageing and the free radical theory. Respiration Physiology 2001; 128(3)379–391
   PubMedGoogle Scholar
• Wolkin A, Jordan B, Peselow E, Rubinstein M, Rotrosen J. Essential fatty acids supplementation in tardive dyskinesia. The American Journal of Psychiatry 1986; 143(7)912–914
   PubMedGoogle Scholar
• Wonodi I, Adami HM, Cassady SL, Sherr JD, Avila MT, Thaker GK. Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. Journal of Clinical Psychopharmacology 2004; 24(6)592–598
   PubMedGoogle Scholar
• Yao JK, van Kammen DP, Welker JA. Red blood cell membrane dynamics in schizophrenia. II. Fatty acid composition. Schizophrenia Research 1994; 13(3)217–226
   PubMedGoogle Scholar
• Youssef HA, Waddington JL. Morbidity and mortality in tardive dyskinesia: Associations in chronic schizophrenia. Acta Psychiatrica Scandinavica 1987; 75(1)74–77
   PubMed Web of Science ®Google Scholar
• Zhang XY, Zhou DF, Cao LY, Xu CQ, Chen da C, Wu GY. The effect of vitamin E treatment on tardive dyskinesia and blood superoxide dismutase: A double-blind placebo-controlled trial. Journal of Clinical Psychopharmacology 2004; 24(1)83–86
   PubMed Web of Science ®Google Scholar
• Zhang ZJ, Zhang XB, Hou G, Yao H, Reynolds GP. Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia. Psychiatric Genetics 2003; 13(3)187–192
   PubMed Web of Science ®Google Scholar